CD₉₆ Expression On Hemopoietic Stem Cells In Acute Leukemia

Objective This study was aimed to investigate the expression of CD₉₆ leukemia stem cells in 91 patients with acute leukemia, and the results were analyzed with clinical pathological data.Methods Flow cytometry was used to detect CD₉₆ molecule on the bone marrow mononuclear cell surface of 91 newly diagnosed patients with acute leukemia, and 15 healthy adults were served as normal controls.Results The average rate of CD₉₆ expression was (53.27±14.43) % in B-ALL stem cells (CD₄₅⁺ CD₃₄⁺ CD₁₉⁺); (87.54±10.02) % in T-ALL stem cells (CD₄₅⁺ CD₃₄⁺ CD₇⁺); and (49.88±5.68) % in AML stem cells (CD₄₅⁺CD₃₄⁺CD₃₈^- ); which was significant difference compared with healthy controls (0.65±0.59) %. After treatment, compared CD₉₆⁺ group CR rate(52%)and CD₉₆⁺ group NR rate (10.6%)with healthy controls, which had significant difference. CD₉₆ average rate in stem cells were detected after treatment. Compared CD₉₆⁺ CR group (1.68±2.31)% with healthy controls, which had no difference. However, compared CD₉₆⁺ NR group (62.39±26.29)% with healthy controls, which had significant difference (p<0.05).The leukocyte, hemoglobin and platelet count in CD₉₆⁺ group had no obvious difference than CD₉₆^- ones. There was no change found in the field of molecular biology and cytogenetic between these two groups.Conclusion CD₉₆ expression is different in different type of leukemia. The positive expression of CD₉₆ on bone marrow hematopoietic stem cells in patients with acute leukemia may be associated with primary drug resistance, replase and progression. The CD₉₆ in hematopoietic stem cells of AL could be a helpful prognostic indicator in treatment response assessment.